查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1376007

重症肌無力治療市場規模、佔有率、趨勢分析報告：依治療類型、最終用途、地區、細分市場趨勢，2023-2030 年

Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Thymectomy, Cholinesterase Inhibitors, Rapid Immunotherapies), By End-use (Hospitals, Clinics), By Region and Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

重症肌無力治療市場的成長與趨勢：

Grand View Research 的最新報告顯示，到 2030 年，全球重症肌無力治療市場預計將達到 42.6 億美元。

預計 2023 年至 2030 年年複合成長率將達到 9.0%。人們對罕見疾病的認知不斷提高、生技藥品的出現以及免疫療法和免疫抑制劑的日益普及正在推動重症肌無力 (MG) 治療市場的發展。

重症肌無力 (MG) 是一種罕見的自體免疫疾病，由抗體介導的神經肌肉傳遞受損引起，導致骨骼肌無力。與這種疾病相關的疾病包括上眼瞼下垂、複視、行走困難和說話困難。重症肌無力患者會出現無痛性肌無力，重複使用會加重肌無力，休息後會改善。

根據美國罕見疾病組織 (NORD) 的數據，美國每 10 萬人中就有 14 至 40 人患有重症肌無力。報告表明，近幾十年來，重症肌無力的發生率一直在增加。這是因為識別患者很容易，而且全世界一般人群中自自體免疫疾病的盛行率不斷增加。重症肌無力在女性中比男性更常見，任何年齡均可出現症狀，但症狀發作通常在 50 至 60 歲之間的男性和 20 至 30 歲之間的女性中達到高峰。

在治療領域，藥物治療佔據最大的市場佔有率，預計在預測期內將保持其市場主導地位。這是因為藥物治療可以在很大程度上控制症狀並顯著抑制免疫系統。藥物包括免疫療法，如 Soliris（依庫麗單抗）、皮質類固醇和免疫抑制劑，如 Prograf（他克莫司）和 Neoral/Sundimmune（環孢素）。然而，新興和欠已開發國家的高治療成本和低認知預計將阻礙市場成長。

重症肌無力治療市場的成長與趨勢：

  • 藥物可以顯著抑制免疫系統並在很大程度上抑制相關症狀。藥物包括免疫療法，如 Soliris（依庫麗單抗）、皮質類固醇和免疫抑制劑，如 Prograf（他克莫司）和 Neoral/Sundimmune（環孢素）。
  • 由於重症肌無力治療的高精度和卓越療效，單株抗體細分市場在2022年佔據最大市場佔有率，超過60%，預計在預測期內將保持主導地位。
  • 根據最終用途，市場分為醫院、診所等。 2022 年，醫院細分市場佔據最大市場佔有率，約為 55%，預計在預測期內將以 9.0% 的複合年複合成長率成長。
  • 到 2022 年，北美市場佔有率最大，超過 50%，預計將在整個預測期內引領市場。
  • 由於免疫抑制劑和單株抗體等醫藥產品的收益增加，預計亞太地區在預測期內將以有利的年複合成長率成長。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 重症肌無力治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 重症肌無力治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 重症肌無力治療：治療類型的估計與趨勢分析

  • 重症肌無力治療市場：重點
  • 重症肌無力治療市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 膽鹼酯酶抑制劑
    • 2018年至2030年膽鹼酯酶抑制劑市場估計與預測
  • 慢性免疫調節劑
    • 2018年至2030年慢性免疫調節劑市場估計與預測
  • 單株抗體
    • 2018年至2030年單株抗體市場預測
  • 快速免疫治療
    • 2018年至2030年快速免疫治療市場估計與預測
  • 切除術
    • 2018年至2030年胸腺切除術市場估計與預測
  • 其他
    • 2018 年至 2030 年其他市場估計與預測

第5章 重症肌無力治療：最終用途估計與趨勢分析

  • 重症肌無力治療市場：重點
  • 重症肌無力治療市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 醫院
  • 診所
  • 其他

第6章 重症肌無力治療市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的重症肌無力治療市場：主要市場點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Alexion Pharmaceutical Inc.
    • Grifols SA
    • Avadel Pharmaceuticals, Plc.
    • Novartis
    • Pfizer, Inc.
    • AbbVie Inc.
    • F.Hoffmann-La Roche AG
    • GlaxoSmithKline Plc.
    • Bausch Health Companies Inc.
    • Shire plc
Product Code: GVR-4-68038-002-6

Myasthenia Gravis Treatment Market Growth & Trends:

The global myasthenia gravis treatment market size is expected to reach USD 4.26 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 9.0% from 2023 to 2030. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Myasthenia Gravis Treatment Market Growth & Trends:

  • Medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine).
  • The monoclonal antibodies segment held the largest market share of over 60% in 2022 and is expected to maintain its leading position through the forecast period, owing to the high precision in treating myasthenia gravis and better efficacy.
  • Based on end use, the market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share of around 55% in 2022 and is expected to grow at a lucrative CAGR of 9.0% over the forecast period.
  • In 2022, North America had the largest market share of over 50% and is projected to lead the market throughout the forecast period.
  • Asia Pacific is anticipated to grow at a lucrative CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment Type
    • 1.1.2. End use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Myasthenia Gravis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Myasthenia Gravis Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Myasthenia Gravis Treatment: Treatment Type Estimates & Trend Analysis

  • 4.1. Myasthenia Gravis Treatment Market: Key Takeaways
  • 4.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Cholinesterase Inhibitors
    • 4.3.1. Cholinesterase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Chronic Immunomodulators
    • 4.4.1. Chronic immunomodulators market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Monoclonal Antibodies
    • 4.5.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Rapid Immunotherapies
    • 4.6.1. Rapid immunotherapies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Thymectomy
    • 4.7.1. Thymectomy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Myasthenia Gravis Treatment: End Use Estimates & Trend Analysis

  • 5.1. Myasthenia Gravis Treatment Market: Key Takeaways
  • 5.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Clinics
    • 5.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Myasthenia Gravis Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Myasthenia Gravis Treatment Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Alexion Pharmaceutical Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Grifols SA
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Avadel Pharmaceuticals, Plc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Novartis
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Pfizer, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. AbbVie Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. F.Hoffmann-La Roche AG
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. GlaxoSmithKline Plc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Bausch Health Companies Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Shire plc
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 3 North America myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 4 North America myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 6 U.S. myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 8 Canada myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Europe myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 10 Europe myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 13 Germany myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 14 UK myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 15 UK myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 16 France myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 17 France myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Italy myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 19 Italy myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Spain myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 21 Spain myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Sweden myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 23 Sweden myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Norway myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 25 Norway myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Denmark myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 27 Denmark myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 31 China myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 32 China myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 34 Japan myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 36 India myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 38 Australia myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Thailand myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 40 Thailand myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 South Korea myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 42 South Korea myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 44 Latin America myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 47 Brazil myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Mexico myasthenia gravis treatment market, by treatment, type 2018 - 2030 (USD Million)
  • Table 49 Mexico myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 51 Argentina myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 56 South Africa myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 60 UAE myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Myasthenia gravis treatment: Market outlook
  • Fig. 9 Myasthenia gravis treatment: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Myasthenia gravis treatment market driver impact
  • Fig. 15 Myasthenia gravis treatment market restraint impact
  • Fig. 16 Myasthenia gravis treatment market strategic initiatives analysis
  • Fig. 17 Myasthenia gravis treatment market: Treatment type movement analysis
  • Fig. 18 Myasthenia gravis treatment market: Treatment type outlook and key takeaways
  • Fig. 19 Cholinesterase inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic immunomodulators market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Rapid immunotherapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Thymectomy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Myasthenia gravis treatment market: End use movement analysis
  • Fig. 26 Myasthenia gravis treatment market: End use outlook and key takeaways
  • Fig. 27 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Global myasthenia gravis treatment market: Regional movement analysis
  • Fig. 31 Global myasthenia gravis treatment market: Regional outlook and key takeaways
  • Fig. 32 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)